IXICO has a strong track record in AD imaging analysis using advanced imaging biomarkers that quantify key AD measurements, such as amyloid plaques, tau targets and brain atrophy, and a technology platform that provides accurate, reproducible volumetric brain segmentations, to provide sponsors with cutting-edge assessments for drug safety, eligibility and efficacy.
With an established reputation in AD research, IXICO has been a key part of high-profile studies, including the Bio-Hermes and AMYPAD initiatives and ongoing collaborations with leading organisations such as ADNI and EPAD.
Amyloid PET, Tau PET, Structural MRI, Vascular pathology, Arterial Spin Labelling (ASL) MRI, Diffusion MRI, Functional MRI, Quantitative Susceptibility Mapping.
Amyloid classification, Tau distribution, Segmentation volumes, Structural MRI (cross-sectional and longitudinal), White matter hyperintensities (FLAIR), Diffusion MRI (Structural Connectivity Microstructural Integrity), Perfusion (cerebral blood flow), Functional MRI and Susceptibility.
Imaging site order management, tracer coordination and oversight, and supply and transportation monitoring.
Our expert neuroradiologists provide a specialised review of MRI scans for ARIA-E and ARIA-H, including microhaemorrhages, macrohaemorrhages, and superficial siderosis. We assess the presence, number, and location of new or evolving findings to support clinical trial safety and decision-making.
Discussing research multi-biomarker advances in Alzheimer’s Disease at ADPD 2025
Innovation Trends in AD Research –the shift to increasingly individualised trial design, therapeutics and care.
Biomarkers and imaging in Alzheimer’s disease: Understanding Amyloid and Tau within the ATN Framework
Imaging of Neurodegeneration within the NIA-AA Research Framework: The ‘N’ in the AT(N) Scheme
Why partnerships are the promising pathway for Alzheimer’s breakthroughs
Advancing AD Trials: Integrating Plasma Biomarkers and Imaging for Precision Enrolment
Imaging - Advancing Biomarker Research for Alzheimer’s Disease Diagnosis
Journal for Clinical Studies Issue 17 April 2025
Exploring how GLP-1 Drugs and vascular biomarkers are shaping Alzheimer’s Disease clinical trial design
AI-Driven Recruitment for Alzheimer’s Disease Clinical Trials: A Pilot Analysis on the A4 Dataset
> Imaging - Advancing Biomarker Research for Alzheimer’s Disease Diagnosis
The Potential of Blood-Based Biomarkers & Digital Assessments in Transforming Research and Clinical Practice